A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial
Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research
ceo
Compass Pathways Appoints a New CEO
George Goldsmith will be replaced as Compass Pathways CEO. Is this good or bad news?
End of content
End of content